These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 35237395)

  • 41. [Update on treatment strategies for mantle cell lymphoma].
    Fukuhara S
    Rinsho Ketsueki; 2024; 65(9):1012-1018. PubMed ID: 39358255
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treating MCL with CAR T Cells.
    Cancer Discov; 2020 Jun; 10(6):OF9. PubMed ID: 32303507
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma.
    Li P; Dong N; Zeng Y; Liu J; Tang X; Wang J; Zhang W; Ye S; Zhou L; Chang AH; Liang A
    Front Med; 2020 Dec; 14(6):811-815. PubMed ID: 32651937
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy.
    Li T; Zhang Y; Peng D; Mao X; Zhou X; Zhou J
    J Immunother Cancer; 2019 Feb; 7(1):51. PubMed ID: 30791947
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma.
    Gauthier J; Maloney DG
    Hematol Oncol Clin North Am; 2020 Oct; 34(5):957-970. PubMed ID: 32861289
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models.
    Chan WK; Williams J; Sorathia K; Pray B; Abusaleh K; Bian Z; Sharma A; Hout I; Nishat S; Hanel W; Sloan SL; Yasin A; Denlinger N; Zhang X; Muthusamy N; Vasu S; de Lima M; Yang Y; Baiocchi R; Alinari L
    Exp Hematol Oncol; 2023 Sep; 12(1):79. PubMed ID: 37740214
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2.
    Wang M; Jain P; Chi TL; Chen SE; Heimberger A; Weathers SP; Zheng L; Rao AV; Rossi JM
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067318
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis.
    Wu JJ; Wade SW; Itani T; Castaigne JG; Kloos I; Peng W; Kanters S; Zoratti MJ; Dreyling M; Shah B; Wang M
    Leuk Lymphoma; 2024 Nov; 65(11):1609-1622. PubMed ID: 38975903
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4-1BB-Based CD19-Directed CAR-T Therapy.
    Yang C; Lei W; Xie H; Wu G; Wei J; Liang A; Qian W
    Onco Targets Ther; 2020; 13():12163-12168. PubMed ID: 33268994
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.
    Reagan PM; Friedberg JW
    Future Oncol; 2021 Apr; 17(11):1269-1283. PubMed ID: 33448873
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies.
    Sawalha Y
    J Pers Med; 2021 Dec; 11(12):. PubMed ID: 34945817
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The present and future for CAR-T cell therapy in adult B-cell ALL.
    Roddie C; Rampotas A
    Blood; 2024 Sep; ():. PubMed ID: 39316713
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma.
    Heini AD; Bacher U; Porret N; Wiedemann G; Legros M; Stalder Zeerleder D; Seipel K; Novak U; Daskalakis M; Pabst T
    Cells; 2022 Sep; 11(17):. PubMed ID: 36078155
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
    Zelenetz AD; Gordon LI; Abramson JS; Advani RH; Andreadis B; Bartlett NL; Budde LE; Caimi PF; Chang JE; Christian B; DeVos S; Dholaria B; Fayad LE; Habermann TM; Hamid MS; Hernandez-Ilizaliturri F; Hu B; Kaminski MS; Karimi Y; Kelsey CR; King R; Krivacic S; LaCasce AS; Lim M; Messmer M; Narkhede M; Rabinovitch R; Ramakrishnan P; Reid E; Roberts KB; Saeed H; Smith SD; Svoboda J; Swinnen LJ; Tuscano J; Vose JM; Dwyer MA; Sundar H
    J Natl Compr Canc Netw; 2023 Nov; 21(11):1118-1131. PubMed ID: 37935098
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
    Avivi I; Goy A
    Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mantle cell lymphoma management trends and novel agents: where are we going?
    Pu JJ; Savani M; Huang N; Epner EM
    Ther Adv Hematol; 2022; 13():20406207221080743. PubMed ID: 35237397
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma.
    Jiang V; Lee W; Zhang T; Jordan A; Yan F; Cai Q; McIntosh J; Vargas J; Liu Y; Wang M
    Biomark Res; 2024 Jun; 12(1):62. PubMed ID: 38886769
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
    Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
    Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma.
    Arun Kumar S; Gao J; Patel SA
    Leuk Res; 2023 Nov; 134():107385. PubMed ID: 37672954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.